文献速递妇科产科

全盆腔质子束扫描放疗用于妇科恶性肿瘤根治或辅助治疗的急性和长期毒性

Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.
PubMed 文献 · Gynecol Oncol · 2023-03-30

回顾性分析23例2013至2019年接受全盆腔质子束扫描放疗的子宫内膜癌、宫颈癌和阴道癌患者,中位随访4.8年,5年局部控制率95.2%,急性和晚期泌尿生殖及胃肠道毒性低,急性血液学毒性最常见(73.9%),可能与化疗比例高有关。

要点

  • 全盆腔质子束扫描放疗后5年局部控制率95.2%,总生存率91.3%。
  • 急性G2-4血液学毒性发生率73.9%,为最常见急性毒性。
  • 晚期G2泌尿生殖毒性和G2胃肠道毒性分别仅13.0%和4.3%。

核心结论

  • 全盆腔质子束扫描放疗用于妇科恶性肿瘤可获得良好的局部区域控制,泌尿生殖和胃肠道毒性发生率低,急性血液学毒性最常见,可能与接受化疗的患者比例高有关。

研究设计与样本

  • 回顾性分析2013至2019年接受全盆腔质子束扫描质子放疗的23例子宫内膜癌、宫颈癌和阴道癌患者,按常见不良事件评价标准第5版分级报告急性和晚期G2及以上毒性,采用Kaplan-Meier法评估疾病结局。

主要发现

  • 中位年龄59岁,中位随访4.8年;子宫内膜癌12例(52.2%)、宫颈癌10例(43.5%)、阴道癌1例(4.3%)。
  • 20例(86.9%)为子宫切除术后治疗,22例(95.7%)接受化疗,其中12例(52.2%)同步化疗。
  • 中位质子放疗剂量为50.4GyRBE(范围45-62.5),8例(34.8%)接受腹主动脉旁/扩大野照射,10例(43.5%)接受近距离放疗推量。
  • 5年局部控制率95.2%、区域控制率90.9%、远处控制率74.7%、疾病控制率和无进展生存率均为71.2%、总生存率91.3%。
  • 急性期G2泌尿生殖毒性2例(8.7%)、G2-3胃肠道毒性6例(26.1%)、G2-4血液学毒性17例(73.9%);晚期G2泌尿生殖毒性3例(13.0%)、G2胃肠道毒性1例(4.3%)、G2-3血液学毒性2例(8.7%);小肠V15Gy平均213.4 cc,大肠V15Gy平均131.9 cc。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize long-term toxicity and disease outcomes with whole pelvis (WP) pencil beam scanning proton radiation therapy (PBS PRT) for gynecologic malignancies. METHODS: We reviewed 23 patients treated from 2013 to 2019 with WP PBS PRT for endometrial, cervical, and vaginal cancer. We report acute and late Grade (G)2+ toxicities, graded by Common Terminology Criteria for Adverse Events, Version 5. Disease outcomes were assessed by Kaplan-Meier method. RESULTS: Median age was 59 years. Median follow up was 4.8 years. 12 (52.2%) had uterine cancer, 10 (43.5%) cervical, 1 (4.3%) vaginal. 20 (86.9%) were treated post-hysterectomy. 22 (95.7%) received chemotherapy, 12 concurrently (52.2%). The median PBS PRT dose was 50.4GyRBE (range, 45-62.5). 8 (34.8% had para-aortic/extended fields. 10 (43.5%) received brachytherapy boost. Median follow up was 4.8 years. 5-year actuarial local control was 95.2%, regional control 90.9%, distant control 74.7%, both disease control and progression-free survival 71.2%. Overall survival was 91.3%. In the acute period, 2 patients (8.7%) had G2 genitourinary (GU) toxicity, 6 (26.1%) had gastrointestinal (GI) G2-3 toxicity, 17 (73.9%) had G2-4 hematologic (H) toxicity. In the late period, 3 (13.0%) had G2 GU toxicity, 1 (4.3%) had G2 GI toxicity, 2 (8.7%) had G2-3H toxicity. The mean small bowel V15Gy was 213.4 cc. Mean large bowel V15 Gy was 131.9 cc. CONCLUSIONS: WP PBS PRT for gynecologic malignancies delivers favorable locoregional control. Rates of GU and GI toxicity are low. Acute hematologic toxicity was most common, which may be related to the large proportion of patients receiving chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Berlin E, Yegya-Raman N, Garver E, et al. Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers. Gynecol Oncol. 2023. PMID: 37003073. doi:10.1016/j.ygyno.2023.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。